Last month, researchers from the University of Washington started conducting an experiment on a decommissioned naval ship in Alameda to test if spraying salt water into the air could brighten clouds and cool the planet. However, their project was forced to stop this month after the city got word of what was going on. SFGate reports: According to a city press release, scientists were ordered to halt the experiment because it violated Alameda's lease with the USS Hornet, the aircraft carrier from which researchers were spraying saltwater into the air using "a machine resembling a snowmaker." The news was first reported by the Alameda Post. "City staff are working with a team of biological and hazardous materials consultants to independently evaluate the health and environmental safety of this particular experiment," the press release states. Specifically, chemicals present in the experiment's aerosol spray are being evaluated to study whether or not they pose any threats to humans, animals or the environment. So far, there isn't any evidence that they do, the city stated.

The prospect of a city-conducted review was not unexpected, the University of Washington said in a statement shared with SFGATE. "In fact, the CAARE (Coastal Aerosol Research and Engagement) facility is designed to help regulators, community members and others engage with the research closely, and we consider the current interactions with the city to be an integral part of that process," the statement reads. "We are happy to support their review and it has been a highly constructive process so far." The marine cloud brightening (MCB) technique involves spraying fine particles of sea salt into the atmosphere from ships or specialized machines. These sea salt particles are chosen because they are a natural source of cloud-forming aerosols and can increase the number of cloud droplets, making the clouds more reflective. The particles sprayed are extremely small, about 1/1000th the width of a human hair, ensuring they remain suspended in the air and interact with cloud droplets effectively.

By reflecting more sunlight, these brightened clouds can reduce the amount of solar energy reaching the Earth's surface, leading to localized cooling. If implemented on a large scale, this cooling effect could potentially offset some of the warming caused by greenhouse gases.

You can learn more about the experiment here.

schwit1 shares a report: Fake studies have flooded the publishers of top scientific journals, leading to thousands of retractions and millions of dollars in lost revenue. The biggest hit has come to Wiley, a 217-year-old publisher based in Hoboken, N.J., which Tuesday announced that it was closing 19 journals, some of which were infected by large-scale research fraud. In the past two years, Wiley has retracted more than 11,300 papers that appeared compromised, according to a spokesperson, and closed four journals. It isn't alone: At least two other publishers have retracted hundreds of suspect papers each. Several others have pulled smaller clusters of bad papers.

Although this large-scale fraud represents a small percentage of submissions to journals, it threatens the legitimacy of the nearly $30 billion academic publishing industry and the credibility of science as a whole. The discovery of nearly 900 fraudulent papers in 2022 at IOP Publishing, a physical sciences publisher, was a turning point for the nonprofit. "That really crystallized for us, everybody internally, everybody involved with the business," said Kim Eggleton, head of peer review and research integrity at the publisher. "This is a real threat." The sources of the fake science are "paper mills" -- businesses or individuals that, for a price, will list a scientist as an author of a wholly or partially fabricated paper. The mill then submits the work, generally avoiding the most prestigious journals in favor of publications such as one-off special editions that might not undergo as thorough a review and where they have a better chance of getting bogus work published.

Philip Ball reports via Scientific American: Thomas Gingeras did not intend to upend basic ideas about how the human body works. In 2012 the geneticist, now at Cold Spring Harbor Laboratory in New York State, was one of a few hundred colleagues who were simply trying to put together a compendium of human DNA functions. Their Âproject was called ENCODE, for the Encyclopedia of DNA Elements. About a decade earlier almost all of the three billion DNA building blocks that make up the human genome had been identified. Gingeras and the other ENCODE scientists were trying to figure out what all that DNA did. The assumption made by most biologists at that time was that most of it didn't do much. The early genome mappers estimated that perhaps 1 to 2 percent of our DNA consisted of genes as classically defined: stretches of the genome that coded for proteins, the workhorses of the human body that carry oxygen to different organs, build heart muscles and brain cells, and do just about everything else people need to stay alive. Making proteins was thought to be the genome's primary job. Genes do this by putting manufacturing instructions into messenger molecules called mRNAs, which in turn travel to a cell's protein-making machinery. As for the rest of the genome's DNA? The "protein-coding regions," Gingeras says, were supposedly "surrounded by oceans of biologically functionless sequences." In other words, it was mostly junk DNA.

So it came as rather a shock when, in several 2012 papers in Nature, he and the rest of the ENCODE team reported that at one time or another, at least 75 percent of the genome gets transcribed into RNAs. The ENCODE work, using techniques that could map RNA activity happening along genome sections, had begun in 2003 and came up with preliminary results in 2007. But not until five years later did the extent of all this transcription become clear. If only 1 to 2 percent of this RNA was encoding proteins, what was the rest for? Some of it, scientists knew, carried out crucial tasks such as turning genes on or off; a lot of the other functions had yet to be pinned down. Still, no one had imagined that three quarters of our DNA turns into RNA, let alone that so much of it could do anything useful. Some biologists greeted this announcement with skepticism bordering on outrage. The ENCODE team was accused of hyping its findings; some critics argued that most of this RNA was made accidentally because the RNA-making enzyme that travels along the genome is rather indiscriminate about which bits of DNA it reads.

Now it looks like ENCODE was basically right. Dozens of other research groups, scoping out activity along the human genome, also have found that much of our DNA is churning out "noncoding" RNA. It doesn't encode proteins, as mRNA does, but engages with other molecules to conduct some biochemical task. By 2020 the ENCODE project said it had identified around 37,600 noncoding genes -- that is, DNA stretches with instructions for RNA molecules that do not code for proteins. That is almost twice as many as there are protein-coding genes. Other tallies vary widely, from around 18,000 to close to 96,000. There are still doubters, but there are also enthusiastic biologists such as Jeanne Lawrence and Lisa Hall of the University of Massachusetts Chan Medical School. In a 2024 commentary for the journal Science, the duo described these findings as part of an "RNA revolution."

What makes these discoveries revolutionary is what all this noncoding RNA -- abbreviated as ncRNA -- does. Much of it indeed seems involved in gene regulation: not simply turning them off or on but also fine-tuning their activity. So although some genes hold the blueprint for proteins, ncRNA can control the activity of those genes and thus ultimately determine whether their proteins are made. This is a far cry from the basic narrative of biology that has held sway since the discovery of the DNA double helix some 70 years ago, which was all about DNA leading to proteins. "It appears that we may have fundamentally misunderstood the nature of genetic programming," wrote molecular biologists Kevin Morris of Queensland University of Technology and John Mattick of the University of New South Wales in Australia in a 2014 article. Another important discovery is that some ncRNAs appear to play a role in disease, for example, by regulating the cell processes involved in some forms of cancer. So researchers are investigating whether it is possible to develop drugs that target such ncRNAs or, conversely, to use ncRNAs themselves as drugs. If a gene codes for a protein that helps a cancer cell grow, for example, an ncRNA that shuts down the gene might help treat the cancer.

An anonymous reader quotes a report from CBS News: Richard "Rick" Slayman, the first human to receive a genetically modified pig kidney transplant, has died almost two months after the procedure. Slayman, who had end-stage kidney disease, underwent the transplant in March at Massachusetts General Hospital in Boston at age 62. The hospital said in a statement on Saturday that there was "no indication" that his death was the result of the transplant. The transplant surgeon had said he hoped the transplant would function for at least two years.

"The Mass General transplant team is deeply saddened at the sudden passing of Mr. Rick Slayman," read the hospital statement. "Mr. Slayman will forever be seen as a beacon of hope to countless transplant patients worldwide and we are deeply grateful for his trust and willingness to advance the field of xenotransplantation." The surgery was a milestone for the field of xenotransplantation -- the transplant of organs from one species to another -- as a way to alleviate the organ shortage for people who need transplants. The effort to genetically modify animal organs is in hopes that the human body will not reject the foreign tissue. NPR notes that there are more than 100,000 people in the U.S. on the waitlist for organs.

An anonymous reader shared this report from the Associated Press: A thick atmosphere has been detected around a planet that's twice as big as Earth in a nearby solar system, researchers reported Wednesday.

The so-called super Earth — known as 55 Cancri e — is among the few rocky planets outside our solar system with a significant atmosphere, wrapped in a blanket of carbon dioxide and carbon monoxide. The exact amounts are unclear. Earth's atmosphere is a blend of nitrogen, oxygen, argon and other gases. "It's probably the firmest evidence yet that this planet has an atmosphere," said Ian Crossfield, an astronomer at the University of Kansas who studies exoplanets and was not involved with the research.

The research was published in the journal Nature.
"The boiling temperatures on this planet — which can reach as hot as 4,200 degrees Fahrenheit (2,300 degrees Celsius) — mean that it is unlikely to host life," the article points out.

"Instead, scientists say the discovery is a promising sign that other such rocky planets with thick atmospheres could exist that may be more hospitable."

"One of the biggest mysteries in astrophysics today is that the forces in galaxies do not seem to add up," write two U.K. researchers in the Conversation: Galaxies rotate much faster than predicted by applying Newton's law of gravity to their visible matter, despite those laws working well everywhere in the Solar System. To prevent galaxies from flying apart, some additional gravity is needed. This is why the idea of an invisible substance called dark matter was first proposed. But nobody has ever seen the stuff. And there are no particles in the hugely successful Standard Model of particle physics that could be the dark matter — it must be something quite exotic.

This has led to the rival idea that the galactic discrepancies are caused instead by a breakdown of Newton's laws. The most successful such idea is known as Milgromian dynamics or Mond [also known as modified Newtonian dynamics], proposed by Israeli physicist Mordehai Milgrom in 1982. But our recent research shows this theory is in trouble...

Due to a quirk of Mond, the gravity from the rest of our galaxy should cause Saturn's orbit to deviate from the Newtonian expectation in a subtle way. This can be tested by timing radio pulses between Earth and Cassini. Since Cassini was orbiting Saturn, this helped to measure the Earth-Saturn distance and allowed us to precisely track Saturn's orbit. But Cassini did not find any anomaly of the kind expected in Mond. Newton still works well for Saturn... Another test is provided by wide binary stars — two stars that orbit a shared centre several thousand AU apart. Mond predicted that such stars should orbit around each other 20% faster than expected with Newton's laws. But one of us, Indranil Banik, recently led a very detailed study that rules out this prediction. The chance of Mond being right given these results is the same as a fair coin landing heads up 190 times in a row. Results from yet another team show that Mond also fails to explain small bodies in the distant outer Solar System...

The standard dark matter model of cosmology isn't perfect, however. There are things it struggles to explain, from the universe's expansion rate to giant cosmic structures. So we may not yet have the perfect model. It seems dark matter is here to stay, but its nature may be different to what the Standard Model suggests. Or gravity may indeed be stronger than we think — but on very large scales only.
"Ultimately though, Mond, as presently formulated, cannot be considered a viable alternative to dark matter any more," the researchers conclude. "We may not like it, but the dark side still holds sway."

Brian Shelton's type 1 diabetes was treated with an infusion of insulin-producing pancreas cells (grown from stem cells). In 2021, the New York Times reported: Now his body automatically controls its insulin and blood sugar levels. Shelton, now 64, may be the first person cured of the disease with a new treatment that has experts daring to hope that help may be coming for many of the 1.5 million Americans suffering from Type 1 diabetes. "It's a whole new life," Shelton said. Diabetes experts were astonished but urged caution. The study is continuing and will take five years, involving 17 people with Type 1 diabetes.
"By fall 2023, three patients, including Shelton, had achieved insulin independence by day 180 post-transplant," MedScape reported (in January of 2024): In the phase 1/2 study, 14 patients with type 1 diabetes and impaired hypoglycemia awareness or recurrent hypoglycemia received portal vein infusions of VX-880 [Vertex Pharmaceutical's pancreatic islet cell replacement therapy] along with standard immunosuppression. As of the last data cut, all 14 patients demonstrated islet cell engraftment and production of endogenous insulin. After more than 90 days of follow-up, 13 of the patients have achieved A1c levels < 7% without using exogenous insulin.
Brian Shelton and another patient died, and while Vertex says their deaths were unrelated to the treatment, they have "placed the study on a protocol-specified pause, pending review of the totality of the data by the independent data monitoring committee and global regulators." (MedScape adds that Vertex "is continuing with a phase 1/2 clinical trial of a different product, VX-264, which encapsulates the same VX-880 cells in a device designed to eliminate the need for immunosuppression.")

And meanwhile, a new study in China (again using stem cell-derived islet tissue) has provided "encouraging evidence that islet tissue replacement is an effective cure for diabetic patients," the researchers wrote in Nature. The treatment was administered to 59-year-old, type-2 diabetic.

"Marked changes in the patient's glycemic control were observed as early as week 2," the researchers write, and after week 32, the patient's Time In Tight Range (TITR) "had readily reached 99% and was maintained thereafter."

Thanks to long-time Slashdot reader hackingbear for sharing the news.

"Does a levitating robot train on the moon sound far-fetched?" asks LiveScience.

"NASA doesn't seem to think so, as the agency has just greenlit further funding for a study looking into the concept." The project, called "Flexible Levitation on a Track" (FLOAT), has been moved to phase two of NASA's Innovative Advanced Concepts program (NIAC) , which aims to develop "science fiction-like" projects for future space exploration. The FLOAT project could result in materials being transported across the moon's surface as soon as the 2030s, according to the agency... According to NASA's initial design, FLOAT will consist of magnetic robots levitating over a three-layer film track to reduce abrasion from dust on the lunar surface. Carts will be mounted on these robots and will move at roughly 1 mph (1.61 km/h). They could transport roughly 100 tons (90 metric tons) of material a day to and from NASA's future lunar base.
"A durable, long-life robotic transport system will be critical to the daily operations of a sustainable lunar base in the 2030's," according to NASA's blog post, arguing it could be used to

• Transport moon materials mined to produce on-site resources like water, liquid oxygen, liquid hydrogen, or construction materials

• Transport payloads around the lunar base and to and from landing zones or other outposts

Thanks to long-time Slashdot reader AmiMoJo for sharing the article.

A tokamak in France achieved a new record in fusion plasma by using tungsten to encase its reaction, which enabled the sustainment of hotter and denser plasma for longer periods than previous carbon-based designs. Quartz reports: A tokamak is a torus- (doughnut-) shaped fusion device that confines plasma using magnetic fields, allowing scientists to fiddle with the superheated material and induce fusion reactions. The recent achievement was made in WEST (tungsten (W) Environment in Steady-state Tokamak), a tokamak operated by the French Alternative Energies and Atomic Energy Commission (CEA). WEST was injected with 1.15 gigajoules of power and sustained a plasma of about 50 million degrees Celsius for six minutes. It achieved this record after scientists encased the tokamak's interior in tungsten, a metal with an extraordinarily high melting point. Researchers from Princeton Plasma Physics Laboratory used an X-ray detector inside the tokamak to measure aspects of the plasma and the conditions that made it possible.

"These are beautiful results," said Xavier Litaudon, a scientist with CEA and chair of the Coordination on International Challenges on Long duration OPeration (CICLOP), in a PPPL release. "We have reached a stationary regime despite being in a challenging environment due to this tungsten wall."

An anonymous reader quotes a report from The Guardian: A British toddler has had her hearing restored after becoming the first person in the world to take part in a pioneering gene therapy trial, in a development that doctors say marks a new era in treating deafness. Opal Sandy was born unable to hear anything due to auditory neuropathy, a condition that disrupts nerve impulses traveling from the inner ear to the brain and can be caused by a faulty gene. But after receiving an infusion containing a working copy of the gene during groundbreaking surgery that took just 16 minutes, the 18-month-old can hear almost perfectly and enjoys playing with toy drums. [...] The girl, from Oxfordshire, was treated at Addenbrooke's hospital, part of Cambridge university hospitals NHS foundation trust, which is running the Chord trial. More deaf children from the UK, Spain and the US are being recruited to the trial and will all be followed up for five years. [...]

Auditory neuropathy can be caused by a fault in the OTOF gene, which makes a protein called otoferlin. This enables cells in the ear to communicate with the hearing nerve. To overcome the fault, the new therapy from biotech firm Regeneron sends a working copy of the gene to the ear. A second child has also recently received the gene therapy treatment at Cambridge university hospitals, with positive results. The overall Chord trial consists of three parts, with three deaf children including Opal receiving a low dose of gene therapy in one ear only. A different set of three children will get a high dose on one side. Then, if that is shown to be safe, more children will receive a dose in both ears at the same time. In total, 18 children worldwide will be recruited to the trial. The gene therapy -- DB-OTO -- is specifically for children with OTOF mutations. A harmless virus is used to carry the working gene into the patient.

The number of tornadoes so far in the United States this year is just above average. But their distribution is changing. From a report: Tornadoes tend to travel in packs these days, often with a dozen or more forming in the same region on the same day. On the worst days, hundreds can form at once. More than a dozen tornadoes were reported on both Monday and Tuesday this week across the Great Plains and the Midwest, according to the Storm Prediction Center run by the National Oceanic and Atmospheric Administration. Two weeks ago, on the most active day in April, 105 tornadoes were reported. While outbreaks like these have always happened, they have become more common in recent decades.

The total number of tornadoes in the United States each year has stayed relatively consistent over the last several decades, but they now happen in more concentrated bursts over fewer days during the year. In the 1950s through the 1970s, on average about 69 percent of tornadoes in the United States happened on days with fewer than 10 tornadoes, and about 11 percent happened on days with 20 or more tornadoes. These percentages have shifted significantly in recent decades, according to a 2019 study. The researchers found that since 2000, on average only about 49 percent of tornadoes have happened on less busy days and about 29 percent have happened on days with 20 or more tornadoes.

"Now when tornadoes happen, they often happen in an outbreak environment," said Tyler Fricker, an assistant professor of geography at the University of Louisiana Monroe and one of the authors of the study. While the timing of this trend lines up with the planet's rising temperatures, scientists are hesitant to definitively attribute tornadoes' clustering behavior to human-caused climate change.

An anonymous reader quotes a report from Interesting Engineering: Imagine exploring the intricate world within a single cubic millimeter of human brain tissue. It might seem insignificant, but within that tiny space lies a universe of complexity -- 57,000 individual cells, 230 millimeters of blood vessels, and a staggering 150 million synapses, the junctions where neurons communicate. All this information translates to a mind-boggling 1,400 terabytes of data. That's the kind of groundbreaking achievement researchers from Harvard and Google have just accomplished.

Leading the charge at Harvard is Professor Jeff Lichtman, a renowned expert in brain structure. Partnering with Google AI, Lichtman's team has co-created the most detailed 3D reconstruction of a human brain fragment to date. This intricate map, published in Science, offers an unprecedented view of the human temporal cortex, the region responsible for memory and other higher functions. Envision a piece of brain tissue roughly half the size of a rice grain but magnified to reveal every cell and its web of neural connections in vivid detail. This remarkable feat is the culmination of nearly a decade of collaboration between Harvard and Google. Lichtman's expertise in electron microscopy imaging is combined with Google's cutting-edge AI algorithms. [...]

The newly published map in Science reveals previously unseen details of brain structure. One such discovery is a rare but powerful set of axons, each connected by up to 50 synapses, potentially influencing a significant number of neighboring neurons. The team also encountered unexpected structures, like a small number of axons forming intricate whorls. Since the sample came from a patient with epilepsy, it's unclear if these formations are specific to the condition or simply uncommon occurrences.

Last week, NASA announced it is working with a technology development company on a new propulsion system that could transport humans to Mars in only two months -- down from the current nine month journey required to reach the Red Planet. Gizmodo reports: NASA's Innovative Advanced Concepts (NIAC) program recently selected six promising projects for additional funding and development, allowing them to graduate to the second stage of development. The new "science fiction-like concepts," as described by John Nelson, NIAC program executive at NASA, include a lunar railway system and fluid-based telescopes, as well as a pulsed plasma rocket.

The potentially groundbreaking propulsion system is being developed by Arizona-based Howe Industries. To reach high velocities within a shorter period of time, the pulsed plasma rocket would use nuclear fission -- the release of energy from atoms splitting apart -- to generate packets of plasma for thrust. It would essentially produce a controlled jet of plasma to help propel the rocket through space. Using the new propulsion system, and in terms of thrust, the rocket could potentially generate up to 22,481 pounds of force (100,000 Newtons) with a specific impulse (Isp) of 5,000 seconds, for remarkably high fuel efficiency. [...]

The pulsed plasma rocket would also be capable of carrying much heavier spacecraft, which can be then equipped with shielding against galactic cosmic rays for the crew on board. Phase 2 of NIAC is focused on assessing the neutronics of the system (how the motion of the spacecraft interacts with the plasma), designing the spacecraft, power system, and necessary subsystems, analyzing the magnetic nozzle capabilities, and determining trajectories and benefits of the pulsed plasma rocket, according to NASA.

An anonymous reader quotes a report from The Hill: Tens of millions of Americans each day breathe in carcinogenic chemicals that are woven into the interiors of their cars, a new study has found. While opening a window can help reduce the risk, only reforms can keep people safe, researchers wrote in a study in Environmental Science and Technology. Approximately 124 million Americans commute each day, spending an average of an hour in their cars. By federal law, the interior of these vehicles are required to contain flame retardants, or chemicals that make it harder for them to combust in a crash. These chemicals have been a legally mandated part of modern cars since the 1970s, when the National Highway Traffic Safety Administration (NHTSA) passed a law requiring their use.

It's arguable how effective this protection is. Patrick Morrison, of the International Association of Firefighters, said in a statement on the study that these chemicals do little to prevent blazes -- but instead simply make them "smokier and more toxic." What the study conclusively demonstrates is that any such protection comes at a price. Virtually all cars investigated by Duke University researchers contained the chemical tris (1-chloro-isopropyl) phosphate, or TCIPP -- which the U.S. National Toxicology Program is investigating as a potential carcinogen. Most cars also had two other phosphate-based flame retardants that the state of California is investigating as potential carcinogens: Those chemicals are tris (1,3-dichloro-2-propyl) phosphate (TDCIPP) and tris (2-chloroethyl) phosphate (TCEP). All three chemicals are linked to reproductive and neurological problems -- particularly because they don't stay in the fabrics they're woven into. Flame retardant chemicals off-gas or leach from the seat and interior fabrics into the air, -- especially in hot weather, when car interiors can reach 150 degrees Fahrenheit. A study from 2017 found that the average U.S. child has lost up to 5 IQ points from exposure to flame retardants in cars and furniture. Meanwhile, adults with the highest levels of flame retardants in their blood face a risk of death by cancer that is four times greater than those with the lowest levels, according to a study published last month.

Ancient Slashdot reader jd shares a report from The Guardian: Neuralink's first attempt at implanting its chip in a human being's skull hit an unexpected setback after the device began to detach from the patient's brain, the company revealed on Wednesday. The patient, Noland Arbaugh, underwent surgery in February to attach a Neuralink chip to his brain, but the device's functionality began to decrease within the month after his implant. Some of the device's threads, which connect the miniature computer to the brain, had begun to retract. Neuralink did not disclose why the device partly retracted from Arbaugh's brain, but stated in a blog post that its engineers had refined the implant and restored functionality.

The decreased capabilities did not appear to endanger Arbaugh, and he could still use the implant to play a game of chess on a computer using his thoughts, according to the Wall Street Journal, which first broke the news of the issue with the chip. The possibility of removing the implant was considered after the detachment came to light, the Journal reported. [...] Arbaugh praised the implant during a demonstration in March and said that it had "already changed his life," while also stating that it had not been perfect and they "have run into some issues."